Feinstein Institutes Expands Vagus Nerve Stimulation Trial for Lupus Patients
Event summary
- Feinstein Institutes' clinical trial for lupus patients using non-invasive vagus nerve stimulation (VNS) is now 50% enrolled.
- The study evaluates pain and fatigue reduction over 28 days of daily stimulation, with an additional 28-day monitoring period.
- Supported by a $450,000 grant from the Lupus Research Alliance over two years.
- Builds on previous successful trial showing VNS efficacy in reducing lupus symptoms.
- Part of Northwell Health’s Center for Bioelectronic Medicine, which explores VNS for multiple autoimmune and inflammatory diseases.
The big picture
The trial underscores the growing momentum in bioelectronic medicine, a field that leverages the gut-brain axis to treat chronic diseases with fewer side effects than traditional pharmaceuticals. Feinstein Institutes' leadership in this space positions it at the forefront of a potential paradigm shift in autoimmune disease treatment. The $450,000 grant from the Lupus Research Alliance highlights the financial backing behind this innovative approach.
What we're watching
- Trial Outcomes
- Whether the trial confirms lasting effects of VNS on lupus symptoms beyond the initial 28-day stimulation period.
- Regulatory Pathway
- The pace at which bioelectronic medicine therapies gain FDA approval following the 2025 approval for rheumatoid arthritis.
- Market Expansion
- How Feinstein Institutes scales VNS applications across other autoimmune and inflammatory conditions.
Related topics
